Browsing by Author Lowenthal, Raymond M.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2015EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma.Espinoza, David; Hudson, Amanda; Long, Anne; Martin, Andrew; Pavlakis, Nick; Stockler, Martin; Thompson, John; Yip, Sonia; Azad, A; Davis, I D; Goldstein, David; Harrision, M; Harvie, R; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Lowenthal, Raymond M.; Nelson, C C; Shapiro, J; Steer, C; NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Central Clinical School: Surgery; NH&MRC Clinical Trials CentreEVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma., Annals of Oncology, vol.26, 6, 2015,pp 1118-1123
2005A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.Bradstock, Kenneth; Brighton, Timothy; Joshua, Douglas; Koutts, Jerry; Young, Graham; Arthur, C; Bashford, J; Baxter, Heather; Cannell, P; Catalano, J; Dunlop, L; Durrant, S; Eliadis, P; Enno, Arno; Gill, D; Gillett, A; Juneja, S K; Leahy, M; Lowenthal, Raymond M.; Matthews, J P; Schwarer, A; Szer, J.; Taylor, Kerry; Western Clinical School: Westmead Millennium Institute; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Western Clinical School: Pathology; Central Clinical School: MedicineA randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine., Blood 2005, vol.105,(2),2005,pp 481-488
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838
2011Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysisBoland, Amy L.; Brown, Christopher; Clarke, Stephen; Gebski, Val; Simes, Robert John; Yip, Sonia; Buck, M; Goldstein, David; Jeffrey, G. Mark; Lowenthal, Raymond M.; Ransom, David T.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSingle-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis, European Journal of Cancer, vol.47, 12, 2011,pp 1826-1836